# US Artificial Pancreas Device System Market

> US Artificial Pancreas Device System Market Research Report By Type (Fully Automated, Semi-Automated, Transcutaneous), By Component (Glucose Sensor, Insulin Pump, Control Algorithm), By End User (Hospitals, Home Care Settings, Diabetes Clinics) and By Technology (Closed Loop Systems, Open Loop Systems, Hybrid Systems) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 19.72%
- **2024:** $ 258.96 Million
- **2025:** $ 310.03 Million
- **2035:** $ 1,875.24 Million
- **Key Players:** Medtronic (US), Insulet Corporation (US), Tandem Diabetes Care (US), Roche (CH), Dexcom (US), Abbott Laboratories (US), Ypsomed (CH), AstraZeneca (GB), Boehringer Ingelheim (DE)

**Report ID:** MRFR/MED/13131-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-artificial-pancreas-device-system-market-14658

---

## Market Summary

## **US Artificial Pancreas Device System Market Overview**

As per MRFR analysis, the US Artificial Pancreas Device System Market Size was estimated at 252.35 (USD Million) in 2023. The US Artificial Pancreas Device System Market Industry is expected to grow from 301.35(USD Million) in 2024 to 3,066.96 (USD Million) by 2035. The US Artificial Pancreas Device System Market CAGR (growth rate) is expected to be around 23.482% during the forecast period (2025 - 2035).

### **Key US Artificial Pancreas Device System Market Trends Highlighted**

The US Artificial Pancreas Device System market is witnessing significant developments driven largely by the growing prevalence of diabetes, particularly type 1 diabetes among children and young adults. Advances in technology are one of the key market drivers, as innovations in continuous glucose monitoring and insulin delivery systems are creating more effective automated solutions for managing blood glucose levels. The acceptance and adoption of connected devices and digital health solutions, amid rising healthcare expenditure in the US, also play a pivotal role in pushing market growth.

There are numerous opportunities to be explored in this market, especially in integrating artificial intelligence and machine learning into existing devices to enhance decision-making processes related to insulin dosing.Moreover, the increasing focus on personalized medicine presents avenues for tailoring artificial pancreas systems to meet individual patient needs more effectively. Continuous patient engagement and education about these devices can further propel adoption rates, which are vital in a nation where diabetes management is imperative for millions.

Recent trends highlight a shift towards systems that are not only automated but also user-friendly and manageable from home, aligning with the broader telehealth trend accelerated by the pandemic. Regulatory support from agencies like the FDA, which aims to streamline approval processes for innovative diabetes technologies, is also encouraging investment and research in this space.Overall, the convergence of technological advancements and regulatory support positions the US Artificial Pancreas Device System market for substantial growth in the coming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Artificial Pancreas Device System Market Drivers**

### **Rising Prevalence of Diabetes in the US**

The US is witnessing a significant increase in diabetes cases, with the Centers for Disease Control and Prevention (CDC) reporting that over 37 million Americans are currently living with diabetes, which is around 11.3% of the entire population. This rise is projected to continue, with estimates suggesting an increase of around 54% in cases by 2030. As the population ages and lifestyle diseases increase, the demand for advanced diabetes management solutions, including the US Artificial Pancreas Device System Market Industry, is expected to grow considerably.

The incorporation of cutting-edge technologies into diabetes management, such as automated insulin delivery systems, directly correlates to the healthcare industry's need to address this urgent health crisis. As organizations like the American Diabetes Association continue to promote education and research around diabetes management, the overall development and adoption of artificial pancreas devices are anticipated to rise in parallel.

### **Advancements in Technology and Innovation**

The rapid advancements in technology, particularly in the fields of sensors, algorithms, and microelectronics, are driving the growth of the US Artificial Pancreas Device System Market Industry. Recent innovations, such as continuous glucose monitoring systems and computational insulin delivery algorithms, have significantly enhanced the clinical efficacy of artificial pancreas devices. This technological evolution is supported by Research and Development (R&D) investments from leading organizations like Medtronic and Dexcom, leading to comprehensive integrated solutions for diabetes management.

Furthermore, the FDA's adaptive regulatory approach, which facilitates the approval of new technologies, enhances the speed at which these devices can make it to the market, fostering further innovation and accessibility.

### **Growing Awareness and Support for Diabetes Management**

There has been notable growth in awareness regarding diabetes management in the US, greatly influenced by campaigns from health organizations, including the American Diabetes Association. With increased knowledge about the risks associated with diabetes, patients and healthcare providers are actively seeking effective solutions, thus propelling the US Artificial Pancreas Device System Market Industry. With more than 50% of diabetics expressing interest in advanced devices, such as the artificial pancreas system for optimum glucose control, there is a clear demand for innovative solutions.

The trends show an increase in direct-to-consumer marketing and outreach initiatives, which enhance patient education and engagement in managing their condition, consequently leading to a greater adoption rate of these advanced technologies.

## **US Artificial Pancreas Device System Market Segment Insights**

### **Artificial Pancreas Device System Market Type Insights**

The US [Artificial Pancreas Device System](../../../reports/artificial-pancreas-device-system-market-6671) Market is experiencing significant advancements, classified primarily into categories such as Fully Automated, Semi-Automated, and Transcutaneous systems, each playing an important role in diabetes management. The Fully Automated segment is particularly noteworthy as it operates with minimal user input, providing continuous glucose monitoring and insulin delivery without constant oversight. This segment is gaining traction due to its potential to enhance patient convenience and adherence, especially among those who struggle with frequent manual management of their diabetes.

On the other hand, the Semi-Automated segment offers a hybrid approach where users still have a degree of control over their insulin delivery, appealing to individuals seeking a balance between automation and personal involvement. This segment is significant for patients who may prioritize personalized care and feel more secure having control while still benefiting from automation.Moreover, the Transcutaneous technology, which allows for insulin delivery through the skin without the need for injections, is an emerging area that could drastically improve user experience by reducing discomfort and fear associated with needles.

As awareness around diabetes and its management continues to grow in the US, driven by factors such as increasing obesity rates and lifestyle changes, the demand for innovative technologies in the Artificial Pancreas Device System Market is expected to rise. Each segment offers its strengths, catering to varied patient needs, hence playing a crucial role in shaping the future of diabetes management.

The integration of these systems into daily routines not only promises enhanced quality of life for users but also signifies a shift towards more automated and efficient healthcare solutions, aligning with broader trends in health technology innovation across the United States. With ongoing Research and Development (R&D) initiatives in this field, these technological advancements are set to redefine diabetes management, thus influencing market growth and segmentation dynamics significantly.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Artificial Pancreas Device System Market Component Insights**

The Component segment of the US Artificial Pancreas Device System Market plays a crucial role in the overall functionality and effectiveness of these advanced medical devices. This segment primarily encompasses Glucose Sensors, Insulin Pumps, and Control Algorithms, each contributing significantly to patient management of diabetes. Glucose Sensors are essential for continuous blood glucose monitoring, providing real-time data that is vital for insulin delivery decisions.

Insulin Pumps act as critical delivery systems, ensuring that patients receive precise insulin doses, thereby improving glycemic control and minimizing the risk of complications related to diabetes.Control Algorithms serve as the brain of the system, interpreting the data from glucose sensors to make informed decisions regarding insulin delivery. This integration of components leads to more personalized and effective diabetes management solutions for patients. The increasing prevalence of diabetes in the US, coupled with advancements in technology, is driving the demand for these components, creating opportunities for market growth.

As healthcare providers seek to improve patient outcomes, the significance of each component becomes evident, making this segment a focal point in the burgeoning US Artificial Pancreas Device System Market.

### **Artificial Pancreas Device System Market End User Insights**

The US Artificial Pancreas Device System Market is profoundly influenced by its End User dynamics, encompassing diverse settings such as Hospitals, Home Care Settings, and Diabetes Clinics, each playing a crucial role in diabetes management. Hospitals are integral as they provide immediate access to advanced technologies and expert healthcare professionals, making them a primary choice for patients with severe diabetes conditions requiring close monitoring and intervention.

Home Care Settings continue to gain traction due to the growing trend towards personalized and convenient diabetes management solutions, enabling patients to self-manage their condition with sophisticated devices, thus enhancing their quality of life.Meanwhile, Diabetes Clinics are pivotal for education and tailored treatment plans, offering specialized care and ongoing support to patients adjusting to new technologies. This diversified End User landscape is essential for the overall efficiency of diabetes care in the US, highlighting the ever-increasing demand for innovative solutions that cater to patient-centric approaches in managing type 1 and type 2 diabetes.

The interplay between these segments reflects the need for continuous advancements in technology and education to support the rising prevalence of diabetes across the country.

### **Artificial Pancreas Device System Market Technology Insights**

The US Artificial Pancreas Device System Market, particularly within the Technology segment, is witnessing substantial evolution driven by advancements in medical technologies and increased diabetes prevalence. Closed Loop Systems have gained prominence due to their ability to automate insulin delivery, thus reducing the burden on patients and enhancing glycemic control. Open Loop Systems, while traditionally used, have a growing influence in terms of integrating with continuous glucose monitoring technology, offering users real-time data to manage their diabetes effectively.

Hybrid Systems are also emerging as a significant innovation, combining features from both closed and open loop designs, providing users with more flexibility and control over their insulin management. The market dynamics are influenced by various factors such as rising obesity rates, increasing awareness regarding diabetes management, and technological advancements that enhance the efficiency and usability of these systems. As the population of insulin-dependent diabetes patients expands, the demand for these innovative solutions is expected to get stronger, leading to an evolving landscape within the US Artificial Pancreas Device System Market.

## **US Artificial Pancreas Device System Market Key Players and Competitive Insights**

The US Artificial Pancreas Device System Market is characterized by its rapid growth and the introduction of innovative technologies aimed at improving diabetes management for patients. As the prevalence of diabetes continues to rise, there has been a notable increase in the demand for advanced medical devices that can automate insulin delivery and promote better glucose control. The competitive landscape in this market is continually evolving, with various key players vying for market share through product differentiation, strategic partnerships, and investments in research and development.

Companies are focusing on enhancing their offerings to meet the diverse needs of individuals suffering from diabetes, while also striving to comply with regulatory standards set by health authorities.

Cureatr stands out as a significant entity within the US Artificial Pancreas Device System Market, leveraging its strengths in digital health technology to make strides in diabetes management. The company is recognized for its expertise in integrating data analytics and digital solutions which enhances patient engagement and empowers healthcare providers. Cureatr's commitment to providing meaningful insights and real-time monitoring differentiates it in this competitive landscape. By focusing on collaborative care solutions, Cureatr has managed to build strong relationships with healthcare professionals and organizations, which boosts its presence in the market.

Moreover, its focus on patient-centric solutions aligns well with the increasing trend of personalized medicine, allowing it to capture the attention of users seeking more tailored management of their diabetes care.

Medtronic, a prominent player in the US Artificial Pancreas Device System Market, has established itself as a leader through its pioneering technologies and comprehensive product offerings. The company is known for its advanced insulin delivery systems and glucose monitoring devices, which are designed to simplify diabetes management for patients. Medtronic's key products include its MiniMed insulin pumps and continuous glucose monitoring systems, which collectively contribute to the functioning of an artificial pancreas system. The company has a robust market presence owing to its significant investments in research and development that drive innovation in its product lines.

Moreover, Medtronic has engaged in strategic mergers and acquisitions that enhance its technological capabilities and expand its portfolio. This proactive approach, combined with effective collaboration with healthcare providers, underscores Medtronic's strengths and solidifies its competitive position in the US market.

### **Key Companies in the US Artificial Pancreas Device System Market Include**

## **US Artificial Pancreas Device System Market Industry Developments**

Recent developments in the US Artificial Pancreas Device System Market have seen significant advancements and activities. In August 2023, Medtronic announced the FDA approval for their advanced hybrid closed-loop system, enhancing glucose control for type 1 diabetes patients. This is part of their ongoing commitment to innovation. Abbott Laboratories has been actively expanding access to continuous glucose monitoring systems, bringing more technology to patients in need. Additionally, Dexcom launched its latest glucose monitoring device, making strides in real-time data sharing capabilities, which is crucial for user engagement.

Mergers and acquisitions remain a focal point, with Insulet Corporation acquiring a stake in CeQur in September 2023, aiming to broaden their product spectrum in diabetes management solutions. Furthermore, Johnson and Johnson announced a strategic partnership with Tandem Diabetes Care in July 2023 to develop integrated devices that further enhance patient experience. The market valuation is witnessing growth, driven by increasing diabetes cases and technological advancements, paving the way for broader adoption of artificial pancreas systems, enhancing the overall management of diabetes and significantly impacting patient outcomes in the US.

## **US Artificial Pancreas Device System Market Segmentation Insights**

### **Artificial Pancreas Device System Market Type Outlook**

### **Artificial Pancreas Device System Market Component Outlook**

### **Artificial Pancreas Device System Market End User Outlook**

### **Artificial Pancreas Device System Market Technology Outlook**

## Market Drivers

### Rising Diabetes Prevalence

The increasing incidence of diabetes in the US is a primary driver for the artificial pancreas-device-system market. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans, or 10.5% of the population, have diabetes. This growing patient population necessitates advanced management solutions, such as artificial pancreas systems, which can automate insulin delivery and improve glycemic control. The demand for these devices is likely to rise as healthcare providers seek effective ways to manage diabetes complications. Furthermore, the economic burden of diabetes, estimated at $327 billion annually, underscores the need for innovative solutions that can enhance patient outcomes and reduce healthcare costs. As awareness of diabetes management options increases, the artificial pancreas-device-system market is expected to expand significantly.

### Technological Advancements in Device Design

Innovations in technology are propelling the artificial pancreas-device-system market forward. Recent advancements in sensor technology, algorithms, and connectivity have enhanced the functionality and reliability of these devices. For instance, the integration of continuous glucose monitoring (CGM) systems with insulin delivery devices has improved real-time data accuracy, allowing for better glycemic control. The market is witnessing a shift towards more user-friendly designs, which may include smartphone applications for monitoring and control. As these technologies evolve, they are likely to attract more users, thereby expanding the market. The artificial pancreas-device-system market is projected to grow at a compound annual growth rate (CAGR) of around 20% over the next five years, driven by these technological innovations.

### Regulatory Approvals and Market Accessibility

Regulatory approvals play a crucial role in shaping the artificial pancreas-device-system market. The US Food and Drug Administration (FDA) has streamlined the approval process for innovative diabetes management devices, which encourages manufacturers to bring new products to market. This regulatory support is essential for fostering competition and innovation within the industry. As more devices receive FDA clearance, patients gain access to a wider range of options, which may enhance their treatment experience. The artificial pancreas-device-system market is likely to see increased growth as regulatory pathways become more efficient, allowing for quicker adoption of new technologies that can improve diabetes management.

### Growing Awareness and Education on Diabetes Care

The increasing awareness and education surrounding diabetes care are pivotal for the artificial pancreas-device-system market. Healthcare providers and organizations are actively promoting the benefits of advanced diabetes management technologies. Educational campaigns aimed at patients emphasize the importance of effective glycemic control and the role of artificial pancreas systems in achieving this goal. As patients become more informed about their treatment options, the demand for these devices is expected to rise. Furthermore, the artificial pancreas-device-system market may benefit from collaborations between healthcare providers and technology companies to enhance patient education and support, ultimately leading to improved health outcomes.

### Increased Investment in Diabetes Management Solutions

Investment in diabetes management solutions is a significant driver for the artificial pancreas-device-system market. Both public and private sectors are channeling funds into research and development to create more effective diabetes management tools. The National Institutes of Health (NIH) has allocated substantial resources towards diabetes research, which includes the development of artificial pancreas systems. Additionally, venture capital investments in health technology startups focusing on diabetes management have surged, indicating a strong belief in the potential of these devices. This influx of capital is likely to accelerate innovation and bring new products to market, further stimulating growth in the artificial pancreas-device-system market.

## Future Outlook

The [Artificial Pancreas Device System Market](https://www.marketresearchfuture.com/reports/artificial-pancreas-device-system-market-6671) is projected to grow at a 19.72% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and rising demand for automated solutions.

**New opportunities:**

- Development of integrated telehealth platforms for remote monitoring and support.
- 
- Expansion into emerging markets with tailored product offerings.
- Partnerships with healthcare providers for bundled service models.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Type: Fully Automated (Largest) vs. Semi-Automated (Fastest-Growing)

The US [artificial pancreas-device-system market](https://www.marketresearchfuture.com/reports/artificial-pancreas-device-system-market-6671) is witnessing a significant distribution of market share among its key segments. The Fully Automated segment currently commands a substantial portion of the market, driven by innovations in technology that enhance user experience and improve health outcomes. Semi-Automated systems, while smaller in share, are rapidly gaining traction due to their affordability and effectiveness, particularly among users who prefer a hands-on approach to management. Growth trends indicate a rising demand for both Fully Automated and Semi-Automated devices fueled by increasing awareness of diabetes management. The drive towards better self-management and convenience is propelling the market forward. Additionally, advancements in technology, combined with supportive regulatory frameworks, are contributing to the attractiveness of these devices, making them a preferred choice for patients.

Fully Automated (Dominant) vs. Semi-Automated (Emerging)

The Fully Automated segment is characterized by sophisticated systems that require minimal user intervention, making them ideal for patients seeking seamless diabetes management solutions. These devices utilize advanced algorithms to continuously monitor glucose levels and adjust insulin delivery in real-time. Conversely, the Semi-Automated segment is classified as an emerging option, appealing to users who want greater control and flexibility. These systems often require users to manually adjust insulin doses, attracting tech-savvy individuals or those looking for a lower-cost alternative. Both segments play crucial roles in the overall landscape, with Fully Automated systems leading in market share while Semi-Automated devices are projected to grow rapidly due to their user-driven advantages.

### By Component: Glucose Sensor (Largest) vs. Insulin Pump (Fastest-Growing)

In the US artificial pancreas-device-system market, the component segment comprises three primary values: Glucose Sensors, Insulin Pumps, and Control Algorithms. Among these, Glucose Sensors command the largest market share, attributed to their critical role in accurate blood glucose monitoring. Insulin Pumps, while less dominant, are experiencing rapid growth, driven by technological advancements and increasing patient adoption seeking more effective diabetes management solutions. The growth trends within the component segment are largely influenced by innovation and increasing awareness of diabetes management. Factors boosting the demand for Insulin Pumps include their improved functionalities and integration with smart technologies. Furthermore, the rising prevalence of diabetes in the US propels continued investment in the research and development of enhanced glucose monitoring systems and insulin delivery methods, thereby fostering a competitive landscape among these components.

Glucose Sensor (Dominant) vs. Insulin Pump (Emerging)

Glucose Sensors are vital in the artificial pancreas-device-system, providing real-time monitoring that aids in effective diabetes management. Their established technology guarantees high accuracy and reliability, positioning them as the dominant force in the market. On the other hand, Insulin Pumps, which deliver insulin more consistently and discreetly, are emerging as a preferred choice due to their convenience and capacity to improve quality of life for users. With advancements in connectivity and integration with apps, Insulin Pumps are set to become increasingly popular, attracting more users who prioritize advanced technology and personalized diabetes care.

### By End User: Hospitals (Largest) vs. Home Care Settings (Fastest-Growing)

The market share distribution for the end user segment highlights hospitals as the largest player, benefiting from established healthcare infrastructures and comprehensive treatment options. Home care settings, while currently smaller in share, show significant growth potential, driven by an increasing shift towards patient-centric care models that emphasize convenience and autonomy for patients managing diabetes. Growth trends in the segment indicate a robust increase in the adoption of artificial pancreas systems across home care settings, attributed to advancements in technology that enable remote monitoring and management. Additionally, rising patient awareness and preference for at-home diabetes management solutions accelerate this trend, making home care settings the fastest-growing segment in the market, alongside ongoing investments in hospital infrastructures to improve diabetes care.

Hospitals (Dominant) vs. Home Care Settings (Emerging)

Hospitals dominate the end user segment due to their comprehensive capabilities in managing complex diabetes cases and providing immediate medical assistance. These institutions have integrated advanced artificial pancreas systems into their diabetes care protocols, ensuring optimal patient outcomes. In contrast, home care settings, while emerging, are rapidly gaining traction as they align with the growing demand for personalized and accessible healthcare solutions. This segment is characterized by an increasing number of patients seeking control over their diabetes management in a familiar environment, leveraging digital health technologies that support autonomy and daily life integration.

### By Technology: Closed Loop Systems (Largest) vs. Hybrid Systems (Fastest-Growing)

The market for artificial pancreas device systems in the US is experiencing significant share distribution among various technology types. Closed Loop Systems dominate the landscape thanks to their automated insulin delivery capabilities and enhanced patient safety features. Meanwhile, Hybrid Systems are quickly gaining ground, appealing to users who require a combination of automated and manual insulin management options, which further diversifies market offerings. Growth trends indicate a rising acceptance of advanced diabetes management solutions, driven by the increasing prevalence of diabetes and the demand for improved patient outcomes. Technological innovations are also fueling this segment's growth, with manufacturers focusing on enhancing system usability and integrating new features like continuous glucose monitoring. The robust investment in research and development is expected to propel the adoption rate of Hybrid Systems as well, making it a dynamic segment in the market.

Technology: Closed Loop Systems (Dominant) vs. Hybrid Systems (Emerging)

Closed Loop Systems represent a dominant force in the artificial pancreas device systems market, characterized by their ability to automatically adjust insulin delivery based on real-time glucose levels. This technology not only streamlines diabetes management but also significantly reduces the risk of hypoglycemia. On the other hand, Hybrid Systems are emerging as a crucial alternative, providing a blend of automated and user-driven control. They are particularly suited for individuals who prefer greater involvement in their management routines while still benefiting from automation. This duality caters to a wider audience and enhances personal choice in treatment, positioning Hybrid Systems as an essential player in the ongoing evolution of diabetes care.

## Competitive Benchmarking

The artificial pancreas-device-system market is currently characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for diabetes management solutions. Key players such as Medtronic (US), Insulet Corporation (US), and Tandem Diabetes Care (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Medtronic (US) focuses on innovation through continuous product development, while Insulet Corporation (US) emphasizes partnerships to expand its reach. Tandem Diabetes Care (US) is leveraging digital transformation to improve user experience, collectively shaping a competitive environment that prioritizes patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive innovation and set industry standards, thereby influencing smaller competitors and new entrants.
In October Medtronic (US) announced the launch of its latest hybrid closed-loop system, which integrates advanced algorithms for real-time glucose monitoring. This strategic move is likely to enhance patient outcomes and solidify Medtronic's leadership position in the market. The introduction of this technology reflects a commitment to innovation and aligns with the growing trend towards personalized diabetes management solutions.
In September Insulet Corporation (US) entered a strategic partnership with a leading tech firm to develop a next-generation insulin delivery system. This collaboration is expected to leverage cutting-edge technology, potentially revolutionizing the way insulin is administered. Such partnerships indicate a shift towards integrating technology with healthcare solutions, enhancing the overall patient experience.
In August Tandem Diabetes Care (US) expanded its product line by introducing a new software update that enhances the functionality of its insulin pumps. This update not only improves user interface but also incorporates machine learning algorithms to predict insulin needs. This strategic enhancement underscores the importance of digital solutions in diabetes management and positions Tandem as a forward-thinking player in the market.
As of November current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into diabetes management solutions. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on technological innovation, reliability of supply chains, and enhanced patient outcomes. This transition suggests that companies that prioritize these aspects will be better positioned to thrive in the evolving landscape.

## Recent News & Developments

Recent developments in the US Artificial Pancreas Device System Market have seen significant advancements and activities. In August 2023, Medtronic announced the FDA approval for their advanced hybrid closed-loop system, enhancing glucose control for type 1 diabetes patients. This is part of their ongoing commitment to innovation. Abbott Laboratories has been actively expanding access to continuous glucose monitoring systems, bringing more technology to patients in need. Additionally, Dexcom launched its latest glucose monitoring device, making strides in real-time data sharing capabilities, which is crucial for user engagement.

Mergers and acquisitions remain a focal point, with Insulet Corporation acquiring a stake in CeQur in September 2023, aiming to broaden their product spectrum in diabetes management solutions. Furthermore, Johnson and Johnson announced a strategic partnership with Tandem Diabetes Care in July 2023 to develop integrated devices that further enhance patient experience. The market valuation is witnessing growth, driven by increasing diabetes cases and technological advancements, paving the way for broader adoption of artificial pancreas systems, enhancing the overall management of diabetes and significantly impacting patient outcomes in the US.

## Report Scope

| MARKET SIZE 2024 | 258.96(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 310.03(USD Million) |
| MARKET SIZE 2035 | 1875.24(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 19.72% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Medtronic (US), Insulet Corporation (US), Tandem Diabetes Care (US), Roche (CH), Dexcom (US), Abbott Laboratories (US), Ypsomed (CH), AstraZeneca (GB), Boehringer Ingelheim (DE) |
| Segments Covered | Type, Component, End User, Technology |
| Key Market Opportunities | Advancements in automated insulin delivery systems enhance patient outcomes in the artificial pancreas-device-system market. |
| Key Market Dynamics | Technological advancements drive innovation in artificial pancreas-device-systems, enhancing patient outcomes and market competitiveness. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US artificial pancreas-device-system market?**
A: The market valuation was $258.96 Million in 2024.

**Q: What is the projected market size for the US artificial pancreas-device-system market by 2035?**
A: The projected valuation for 2035 is $1875.24 Million.

**Q: What is the expected CAGR for the US artificial pancreas-device-system market during the forecast period 2025 - 2035?**
A: The expected CAGR is 19.72% during the forecast period.

**Q: Which companies are the key players in the US artificial pancreas-device-system market?**
A: Key players include Medtronic, Insulet Corporation, Tandem Diabetes Care, Roche, Dexcom, Abbott Laboratories, Ypsomed, AstraZeneca, and Boehringer Ingelheim.

**Q: What are the main segments of the US artificial pancreas-device-system market?**
A: The main segments include Type, Component, End User, and Technology.

**Q: What was the valuation of the Fully Automated segment in 2024?**
A: The Fully Automated segment was valued at $50.0 Million in 2024.

**Q: How much is the Insulin Pump component projected to be worth by 2035?**
A: The Insulin Pump component is projected to reach $763.12 Million by 2035.

**Q: What is the expected valuation for Home Care Settings in the US artificial pancreas-device-system market?**
A: Home Care Settings is expected to be valued at $800.0 Million by 2035.

**Q: What is the projected valuation for Closed Loop Systems by 2035?**
A: Closed Loop Systems is projected to reach $735.12 Million by 2035.

**Q: How does the market performance of the US artificial pancreas-device-system compare across different technologies?**
A: The market performance varies, with Closed Loop Systems expected to be valued at $735.12 Million, while Open Loop Systems and Hybrid Systems are projected at $564.12 Million and $576.0 Million, respectively.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-artificial-pancreas-device-system-market-14658*